Combo Superior to Sunitinib in Advanced Renal Cell Carcinoma

Avelumab-axitinib regimen offers better progression-free survival and responses than sunitinib for patients with previously untreated advanced RCC, regardless of risk group or PD-L1 status.

from Latest articles from Cancer Therapy Advisor News http://bit.ly/2NbO0d8